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OBJECTIVES:With rapid ageing, prevalence of dementia in the elderly is increasing
at a fast rate. This study aimed to examine themedical expenditure for dementia in
the elderly and to analyze factors affecting its expenditure in South Korea.
METHODS:We analyzed the data of sampled patients from National Health Insur-
ance. Direct medical costs including hospitalization, out-patient service and phar-
macy costs were calculated from claims of patients in 2010. To examine the deter-
minants of costs, we used a two-part model to deal with the zero values of
expenditure. The first part predicted the probability of any expenditure with a
logistic regression while the second part used an OLS regression model with log-
transformed expenditure. RESULTS: Average medical expenditure in the total of
3729 dementia patients was 5.6 million won. Average expenditure increased with
severity (p0.004). In the first part, patients in the long-term care facilities had a
lower probability of expensing medical costs than patients with family-based care
(OR0.30, 95% CI 0.21-0.43). The probability of incurring expenditure was much
higher for severe patients thanmild patients (OR1.33, 95% CI 1.02-1.74). Among
the patients with expenditure, better educated (elementary, middle school gradu-
ates and high school graduates) spent more costs than under educated (less than
elementary graduates) patients (17%, 27%, respectively) (p0.05). Cost estimates
demonstrated that education levels, facility care and types of dementia were sig-
nificantly associated with the costs. Interestingly, the costs were 20% lower for
severe patients versus mild patients because outpatient and pharmacy costs de-
creased as the severity increases. CONCLUSIONS: This study showed a burden of
medical expenditure for dementia and associations between various factors and
costs. Costs were significantly different among conditions. However, this study
considered only medical costs for dementia. Therefore, further research needs to
include non-medical costs and indirect costs for dementia.
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OBJECTIVES: To review the consequences associated with schizophrenia relapse.
METHODS:We searched the Medline, EBSCO and EMBASE up to February 2012 for
eligible studies. Included studies were systematic reviews, meta-analyses, pro-
spective observational studies, retrospective cohort studies or randomized con-
trolled trials (RCTs) measuring the cost consequences of schizophrenia relapse or
recurrence. The consequences from studies with different designs, countries and
years were compared. RESULTS: Eleven studies conducted in Europe, United
States, Germany, England, Australia, Japan and Brazil were identified and re-
viewed. Relapse in schizophrenia were characterized by higher rates of hospital-
ization, day hospital visit and psychiatric visit; longer inpatient days and more
medications. Schizophrenia patients with relapse incurred significantly higher to-
tal annual direct medical costs, which were almost 2 to 4 times of those without
relapse. The absolute annual cost of relapsed schizophrenia patients changed tre-
mendously in different countries, approximately ranging from 1,198 USD (in 2006
USD) in Brazil to 50,986 USD (in 2000 USD) in the United States. The average cost of
a relapse was 3421 EUR (in 2005 EUR). The driving part of the cost difference was
attributed to inpatient care. Higher frequencies of reemergence of psychotic symp-
toms and aggravation of positive or negative symptoms were observed in these
studies. Significant differences in patient quality of life in favor of patients without
relapsewere captured in some of the studies, while in other studies the differences
were insignificant. The most frequently employed quality of life measurements
were PANSS, CGI, GAF, Lehman QoL, EQ-5D, MLDL GI and SF-36. CONCLUSIONS:
The findings of the review confirmed the significant economic burden of schizo-
phrenia relapse, and showed such costs were mainly driven by more hospitaliza-
tions and longer duration of hospitalization. The cost consequence of relapse var-
ies among countries. Relapse causes deterioration in patient quality of life as well.
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OBJECTIVES:To analyze the cost consequences associatedwith non-compliance in
schizophrenia treatment.METHODS:We searched the Pubmed, EBSCO, Adis Phar-
macoEconomics, Wiley, Springer and Elsevier up to February 2012 for eligible stud-
ies using the key words of schizophrenia, compliance, adherence and cost. In-
cluded studies were systematic reviews, meta-analyses, prospective observational
studies and retrospective cohort studies measuring the cost consequences related
to non-compliance of anti-psychotic medication. The cost consequences from dif-
ferent studies were compared. RESULTS: Six primary studies and seven literature
reviews were identified and included in this analysis, of the primary studies 2 in
UK, 1 in Sweden, 1 in Canada and 1 in Taiwan. Non-compliance with treatment is
the main driver of relapses and re-hospitalizations which cause significant eco-
nomic burden to patients and their families. Schizophrenia patients who were not
compliant with treatment hadmore relapses, higher rates of hospitalizations, lon-
ger hospitalization days,more needs for intensive care,more psychiatric visits, and
more medications. One of the UK studies showed that non-compliant patients
incurred significantly higher total annual direct medical costs, which were almost
1.5 times of those who were compliant with treatment. The other 5-year UK study
showed that if we improve compliance rate for a patient by 20%, £16,147 will be
saved and 0.55 relapse will be avoided for the patient. Three studies showed a
significant increase of compliance by using long-acting Risperidone injection com-
pared with oral anti-psychotics and long-acting typical anti-psychotic injections
which may result in cost savings and improvement in patient quality of life.
CONCLUSIONS: The findings of the review showed significant cost saving by in-
creasing compliance with treatment due to reductions in relapse and re-hospital-
ization. Long-acting Risperidone injection can significant increase the compliance
of medication which may result in cost savings.
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OBJECTIVES: To compare cost-effectiveness of Agomelatine versus Escitalopram-
Venlafaxine matrix comparator in terms of Life Year in Remission (LYR) and Qual-
ity Adjusted Life Year (QALY).METHODS: A discrete event simulation hypothetical
model was developed to describe the course of depressive disorders treatment in
Thai setting. A sample size of 250,000 depressed patients and 1,000 simulations
were generated. Antidepressants were analysed for treatment of acute phase
(12-24 weeks), continuation phase (6-9 months) and maintenance phase (over 2
years of follow-up). Model was based on real Thai data, which acquired from public
data, including disease parameters, costs of antidepressants, costs of medication
treatments for insomnia and sexual side-effects, costs of cognitive behavioral
therapy(CBT) and electroconvulsive therapy(ECT), mean costs of psychiatric visits
and mortality data. Impact measures were derived from a systematic review and
meta-analysis of international literature. Willingness to pay was set at 300,000
THB/QALY. Results were presented as costs (Thai Baht currency) per QALY and per
LYR averted, compared to thematrix comparator which contained 41.8% venlafax-
ine-treated and 58.2% escitalopram-treated in real Thai data. Model simulation
initiated with either Agomelatine 25 mg or a Matrix comparator (80% with Escita-
lopram 10mg, 20% with Escitalopram 20mg 20% or Venlafaxine150 mg). Relapse
cases need treatment assumed addition of Sertraline, CBT and ECT. RESULTS: The
IncrementalCost-EffectivenessRatios (ICER)ofAgomelatine forepisodic treatmenteither
with or without a continuation of maintenance phase at base case was more effective
than thematrix comparator by177,008THB per LYR and100,767THB per QALY. Prob-
abilistic sensitivity analysis supported thatAgomelatinewasmore cost effective than the
matrix comparator at probability above 0.75. CONCLUSIONS: In Thai setting, Agomala-
tinewasamorecost-effective treatmentoption fordepressivedisordersascompared toa
matrix comparator of EscitalopramandVenlafaxine.
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OBJECTIVES: To evaluate the cost-effectiveness of Risperidone long-acting injec-
tion (LAI) in schizophrenia treatment. METHODS: We searched medical literature
using key words risperidone, long-acting, cost-effectiveness, pharmacoeconomics
and economic evaluation in Medline, Embase, Elsevier and Ovid databases up to
January 2012. Literature review studies were excluded from this review. RESULTS:
Twelve primary study articles were indentified and included in this review of
which 2 in Germany, 2 in Sweden, 1 in US, 1 in France, 1 in Belgium, 1 in the UK, 1
in New Zealand, 1 in Canada, 1 in China Mainland, 1 in Taiwan. All studies only
calculated the direct costs of treatments, including hospitalizations, medications,
and consultations. Ten studies showed cost savings while the rest 2 studies con-
cluded Risperidone LAI was more cost-effective than comparators. Among the 10
studies showing cost savings, 4 studies further demonstrated better efficacy of
Risperidone LAI than oral psychotics and Haloperidol long-acting injection, 4 stud-
ies showed a range of 0.22-0.55 relapses reduction with Risperidone LAI treatment
resulting in significant cost savings, 2 studies showed a 0.043-0.103 QALY gained
per patient in 5 years with Risperidone LAI, 3 studies compared the inpatient days
and hospitalization frequencies before and after using Risperidone LAI with fewer
inpatient days and hospitalizations after Risperidone LAI treatment. Among the 2
studies showing Risperidone LAI wasmore cost-effective, the study in ChinaMain-
land showed Risperidone LAI was more cost-effective than Olanzopine and Que-
tiepine while the study from Taiwan found Risperidone LAI was more cost-effec-
tive than Olanzopine and depot haloperidol. CONCLUSIONS: Based on the
available studies, this systematic review found that Risperidone LAI was a cost-
effective treatment for schizophrenia patients.
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OBJECTIVES: Schizophrenia has been found to be associated with poor medication
adherence, and a higher prevalence of diabetes. As appropriate adherence to hy-
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poglycemic therapy is crucial for good glycemic control, this study aimed to com-
pare medication adherence to oral hypoglycemic therapy, as well as diabetic care
and risk of acute complications between type II diabetics with schizophrenia ver-
sus those without schizophrenia.METHODS: This study used the National Health
Insurance claims data of a randomly selected sample. Enrollees who had received
oral hypoglycemic therapy in 2002 and had been diagnosed with schizophrenia
were included in the study (the case group). Enrollees without schizophrenia who
had received oral hypoglycemic therapy in 2002were selected tomatch the age and
gender of the case group (1:3) (the comparison group). All subjects were observed
for one year after their index dates – the dates of their first filled prescriptions in
2002. Medication possession ratio (MPR) was measured as MPR0.8 indicated poor
adherence. Indicators of diabetic care included blood glucose test and HbA1c test.
Acute complicationswere defined as emergency roomvisits or hospital admissions
due to coma, hypoglycemia, hyperglycemia, or diabetic ketoacidosis. Logisticmod-
els were used to evaluate likelihood of poor medication adherence and access to
diabetic care. Cox proportional hazards model was adopted to assess risk of acute
complications. RESULTS: There were 202 and 606 subjects in the case group and
comparison group, respectively. The mean age was 52, and 48% were male. Ap-
proximately half of both groups were poorly adherent to their oral hypoglycemic
therapy. Diabetics with schizophrenia were less likely to receive HbA1c test. Their
risks of acute complications were comparable. CONCLUSIONS: According to our
preliminary results, diabetics with schizophrenia, compared with those without
such a condition, had worse diabetic care. Better disease management will be
necessary for this patient group.
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OBJECTIVES:The impact of dementia andAlzheimer’s disease (AD) are devastating
onmany levels, including the effects on the families/caregivers of the patient. This
study was designed to describe and evaluate the characteristics of a cohort of
Chinese dementia patients, including associated caregivers’ burden.METHODS: A
3-month open-enrollment, multi-center study was conducted at 48 tier 3 hospitals
across mainland China in 2009. Caregivers who accompanied dementia patients
were asked to participate in the caregiver assessment survey. Interviews included
information on caregiver profile, patient care, and caregivers’ burden. Caregiver
burden was measured using the Chinese version of the validated Zarit Burden
Interview (ZBI). Disease severity was measured by the Clinical Dementia Rating
(CDR). RESULTS: A total of 1425 dementia patients with 1387 associated caregivers
completed the Chinese version of the ZBI. Dementia patients from this cohort were
considered to have mild to moderate dementia (mean CDR score 1.67 [SD0.79]).
ADwas themost commondementia subtype among this cohort (46.7%) followed by
vascular dementia (28.7%). Among the caregivers who participated in this survey:
57% were female, 51% identified as the spouse of the dementia patient, and 67.3%
had been caring for the dementia subject more than one year. Dementia caregiver
burden was mild to moderate (mean total ZBI score of 26.6), regardless of age,
gender, level of education, type of dementia, CDR, and duration of care. The care-
giver burden increases over time and is associated with the progression of the
disease. CONCLUSIONS: Dementia has significant emotional and social impact
(measured by ZBI) on patients and caregivers, regardless of demographics and
geography. In China, these challenges may be mitigated by improving public edu-
cation and increasing public awareness on the signs and symptoms of dementia vs
normal aging.
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OBJECTIVES: This study with in-centre haemodialysis patients examined the im-
pact of personal psychological resilience resources, social support, hopefulness,
and perceived loss of control to doctor on mental health outcomes. We hypothe-
sized that resilience resources are the overarching principle determining QOL
among these predictors. METHODS: Non-invasive study with cross-sectional de-
sign, using quantitative data collected from standardized self-report measures
(N294). Predictor variables included: resilience resources (perceived control, op-
timism, self-esteem); social support; loss of control to doctor; hope. Control vari-
ables included: gender; age; relationship, vocational, socio-economic status; living
alone; cultural identity; religious beliefs; and disease-related variables such as
cause of renal failure, number of co-morbidities, time since dialysis onset, trans-
plant status, kidney disease impact. Outcome measure: Mental Composite Score
(MCS) of SF-36v2® health survey. RESULTS: Only questionnaires without missing
data were included in the analysis (n219). Significant relationships (p0.01) were
observed of MCS with employment status (r0.25); socioeconomic status (r.30);
kidney disease impact (r0.60); social support (r0.21); hope (r0.27); loss of con-
trol to doctor (r0.16); self-esteem (r.51); optimism (r0.40); perceived control
(r.40). Hierarchical multiple regressionmodel explained 48 percent of variance in
MCS, F(9,209)23.04, p.01. Demographic variables (block 1, 
R2.12,
F(2,216)15.24, p0.01), disease impact (block 2, 
R2.29, F(1,215)104.15, p0.01),
and resilience resources (block 4, 
R2.08, F(3,209)11.48, p0.01) explained a sig-
nificant portion of variance inMCS. Social support, hopefulness, and perceived loss
of control to doctor (block 3, 
R20.01, F(3,212)0.70) were not able to explain a
significant portion of variance in MCS. CONCLUSIONS: Resilience resources ac-
counted for 8 percent of variance over and above all other predictors. Confirming
the hypothesis, variables such as social support that had predicted mental health
in earlier studies became insignificant. Future research should identify less resil-
ient patients andmake positive psychology approaches available to see if outcome
can be improved in clinical practice.
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OBJECTIVES: To investigate the irrational prescription habit of steroids by medical
practitioners in patients with arthritis and lower back pain in the area.METHODS:
Twenty-nine pharmacies were randomly selected in various areas of the Province
and 321 prescriptions of those patients with complaints of arthritis or lower back
pain were evaluated for use of steroids (corticosteroids). RESULTS: A total of 103
out of 321 prescriptions (about 30 %) were containing corticosteroids and the pa-
tients were using these steroids mostly in an irrational manner. These prescrip-
tions were prescribed by medical practitioners of all specialties including orthope-
dics. A small number of non medical doctors (about 2%) were also responsible for
the steroids prescriptions. CONCLUSIONS: This study indicates that this type of
irrational practice is the reflection of state and regulatory affairs in the country and
this is a warning for all developing countries which need strict regulations for
steroid prescriptions.
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OBJECTIVES: Using a national database to evaluate the risk of ONJ in osteoporosis
females in Taiwan. METHODS: We used the population-based National Health
Insurance (NHI) database in Taiwan to conduct a retrospective cohort study during
the period from 2000 through 2008. The study population confined to the women
who took alendronate or raloxifene initially from Jan, 2001 to Sep, 2005 and medi-
cation needed to be stably prescribed for 90 days. The measurements of clinical
outcomes includedONJ-diagnosis (ICD-9-CMdiagnosis code 526.4, 526.5, 528.3, and
730.18) and sequestrectomy (NHI payment code: 92025B and 92026B) within 3 years
after stable medication use. Cox’s proportional hazard model was used to analyze
the risk of ONJ development. RESULTS:We identified 23,158 womenwho had been
prescribed either alendronate (n  18,504) or raloxifene (n  4,654). The patients
treated with alendronate were at a higher risk of ONJ-diagnosis compared with the
raloxifene group (hazard ratio [HR]  1.336 [95% CI, 1.100-1.622]). For sequestrec-
tomy, patients took alendronate also had a higher risk than raloxifene group
(HR4.648 [95% CI, 1.120-19.291]). CONCLUSIONS: Patients who took alendronate
had a higher risk of ONJ than raloxifene patients, nomatter from the perspective of
having the diagnosis or performing sequestrectomy. When undertaking the bis-
phophonates treatment, doctors need to pay attention to the oral condition of
patients.
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OBJECTIVES: In this research, anti-inflammatory effect of Stachys Fruticulosa-
M.Bieb. extract was studied in rats. METHODS: The effect of the extract against
acute inflammation was studied by hind paw edema test. Intraperitoneal injection
of different doses (50, 100, 200 and 300 mg/kg) of Stachys Fruticulosa which was
followed by hind paw carageenan injection 1 h later were investigated. The resul-
tant edema was quantified by measuring the hind paw edema with three ways of
measurement: micrometer method, paw circumference (PC), plethysmometer
method. RESULTS: After 2, 4 and 6 h we measured the anti-inflammatory effect of
Stachys Fruticulosa extract. Stachys Fruticulosa extract with doses of 100, 200 and
300 mg/kg and indomethacin at a dose of 5 mg/kg showed significant effect.
CONCLUSIONS: It is concluded that themethanolic extract of Stachys fruticulosa -
M.Bieb. has anti-inflammatory effect which can be used as an alternative for Indo-
methacin for treatment of inflammation. Also it might be advantageous to use this
herbal drug as a synergist for Indomethacin anti-inflammatory effects, to lower the
dosage and consequently.
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A RANDOMIZED, PLACEBO CONTROLLED TRIAL TO COMPARE SAFETY AND
EFFICACY BETWEEN CURCUMA LONGA LINN EXTRACT [NR-INF-02],
GLUCOSAMINE SULPHATE AND COMBINATION OF TWO IN THE TREATMENT
OF PAINFUL KNEE OSTEOARTHRITIS
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OBJECTIVES: Osteoarthritis [OA] a common, chronic disabling condition in ortho-
paedic practice is routinely treated with non-steroidal anti-inflammatory drugs
[NSAIDs] which are often associated with serious adverse reactions while long
term Glucosamine sulphate [GS] is frequently used to halt its progression. Objec-
tive of this studywas to compare safety and efficacy of herbal formulationNRINF02
and Glucosamine sulphate alone and their combination with placebo in treatment
of patientswithOA.METHODS:A randomized, single blind, placebo controlled trial
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